Real-World Treatment Patterns, Healthcare Use and Costs in Triple-Class Exposed Relapsed and Refractory Multiple Myeloma Patients in the USA
Open Access
- 2 December 2020
- journal article
- research article
- Published by Taylor & Francis in Future Oncology
- Vol. 17 (5) , 503-515
Abstract
Aim: To estimate treatment patterns and healthcare costs among triple-class exposed relapsed and refractory multiple myeloma (RRMM) patients. Materials & methods: Eligible patients had ≥1 line of t... Lay abstract Treatment of multiple myeloma (MM) has evolved rapidly over recent decades, with the introduction of immunomodulatory drugs, proteasome inhibitors and the anti-CD38 monoclonal antibody...Keywords
Funding Information
- Bristol-Myers Squibb
This publication has 22 references indexed in Scilit:
- Development of CAR-T cell therapies for multiple myelomaLeukemia, 2020
- Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.Journal of Clinical Oncology, 2020
- Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).Journal of Clinical Oncology, 2020
- Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real‐life outcomes of daratumumab treatmentEuropean Journal of Haematology, 2020
- First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter TrialBlood, 2019
- Burden of disease progression in patients with multiple myeloma in the USLeukemia & Lymphoma, 2019
- Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapyLeukemia, 2019
- Daratumumab resistance is frequent in advanced‐stage multiple myeloma patients irrespective ofCD38 expression and is related to dismal prognosisEuropean Journal of Haematology, 2018
- The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple MyelomaCancers, 2017
- Multiple myeloma: patient outcomes in real‐world practiceBritish Journal of Haematology, 2016